Trodelvy Shows Superiority to Chemo for Advanced TNBC in Phase 3 Trial

Trodelvy Shows Superiority to Chemo for Advanced TNBC in Phase 3 Trial
Trodelvy (sacituzumab govitecan), compared with standard chemotherapy, significantly prolonged overall survival and improved the overall response rate of patients with metastatic triple-negative breast cancer (mTNBC) who had at least two prior lines of therapy, a Phase 3 trial reported. Based on these findings, recently presented as a late-breaking abstract at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, the therapy’s developer, Immunomedics, intends to file a request for Trodelvy's full approval for this patient group by year's end. “We believe these remarkable results should facilitate the establishment of Trodelvy as a new standard of care in patients with third-line mTNBC,” Loretta M. Itri, the company's chief medical officer, said in a press release. Immunomedics will submit a supplemental application to the U.S. Food and Drug Administration (FDA) with these confirmatory trial data to support T
Subscribe or to access all post and page content.

Pin It on Pinterest

Share This